HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, today announced a partnership with HeartNexus Inc., a network of board-certified cardiologists specializing in cardiac test interpretation, peer consultations, and telemedicine visits. The collaboration enables HeartBeam to offer 24/7 cardiology reader services for patients experiencing cardiac symptoms outside traditional care settings. Using HeartBeam’s patented 3D technology, patients can capture a 30-second, cable-free ECG recording anytime symptoms occur, transmitting the data to HeartNexus cardiologists for immediate interpretation.
“Working with HeartNexus accelerates our mission to make medical-grade cardiac monitoring accessible beyond the walls of a medical facility,” said Robert Eno, CEO of HeartBeam. The partnership expands HeartBeam’s ecosystem with real-time cardiology feedback and future integration of AI wellness and wearable features. This development is significant because it bridges the gap between intermittent cardiac monitoring and continuous clinical oversight. Patients who experience sporadic symptoms such as palpitations, dizziness, or chest discomfort can now capture a high-quality ECG at the moment of symptoms and receive an expert interpretation within minutes, potentially reducing unnecessary emergency room visits and enabling earlier detection of arrhythmias or other cardiac issues.
The partnership leverages HeartBeam's FDA-cleared 3D vector electrocardiography (VECG) technology, which collects signals from three non-coplanar directions and synthesizes them into a 12-lead ECG. This platform is designed for portable use, allowing patients to record medical-grade ECGs without cables or the need for a clinical setting. Real-time interpretation by HeartNexus cardiologists adds a critical layer of immediate clinical decision support. For healthcare providers, this means patients can be triaged more effectively, and those with normal recordings can be reassured without visiting a hospital.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and its 12-Lead ECG synthesis software is currently under FDA review. The company holds over 20 issued patents related to its technology. This partnership comes at a time when remote patient monitoring and telehealth services are expanding rapidly, driven by the need for accessible, cost-effective cardiac care. The integration of AI wellness and wearable features mentioned by Eno suggests future enhancements that could further automate analysis and expand the device's use for chronic condition management.
For more information on the partnership, the full press release is available at https://ibn.fm/HqwuQ. To stay updated on HeartBeam's news, visit the company’s newsroom at https://ibn.fm/BEAT. This article contains forward-looking statements, and readers are encouraged to review the company's filings with the SEC for a discussion of risks and uncertainties.
